Elan/Biogen Idec’s Antegren (Natalizumab) for Treatment of Multiple Sclerosis
July 26, 2004 by admin · Leave a Comment
On July 26, 2004 Elan Corp.’s application for approval of its multiple sclerosis (MS) drug Antegren was accepted for review by the FDA. Elan has developed Antegren with U.S. partner Biogen Idec. The company has stated that this therapy represents a new approach in the treatment of MS and is expected to eventually generate annual [...]
ID Biomedical’s FluInsure Influenza Vaccine
July 20, 2004 by admin · Leave a Comment
FluInsure™ On July 20 2004, ID Biomedical released preliminary data regarding FluInsure™ from its field efficacy study. Carried out during the 2003-2004 flu season at 28 sites throughout Canada, this study involved 1,349 healthy participants aged 18 to 64. A single dose of the nasally delivered, non-living vaccine had 67% efficacy (3/451 vs. 9/443 placebo) [...]
Neurochem’s Alzhemed for treatment of Alzheimer’s
July 18, 2004 by admin · Leave a Comment
On July 18, 2004, Neurochem Inc. released interim data pertaining to a Phase II open-label extension study of the effects of Alzhemed on cognitive function and global measure of performance in patients with mild-to-moderate Alzheimer’s Disease. According to Neurochem, the study showed that approximately 70% of the mild AD patients had stabilized or improved cognitive [...]
CV Therapeutics’ Ranexa for Chronic Angina
April 20, 2004 by admin · Leave a Comment
On April 20, 2004 CV Therapeutics released data from its Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial. The company reported that patients with chronic angina taking Ranexa™ (ranolazine) had a statistically significant increase in symptom-limited exercise duration at trough drug concentrations. The MARISA clinical trial is a double blind, placebo controlled study involving [...]